RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $142

RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $128 to $142.